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Our current antiseizure drugs treat the symptoms of epilepsy but do not alter the course of the disease. Ideally, an antiepileptogenic therapy could be administered either soon after an acute brain insult to prevent the development of epilepsy, or after an epilepsy diagnosis to slow or reverse the naturally progressive worsening of the disease. If an ideal treatment were truly antiepileptogenic and did not simply suppress seizures, it could eventually be discontinued and the patient would remain seizure-free. Although there are no antiepileptogenic therapies in clinical use, preclinical studies have identified several potential antiepileptogenic compounds that act on a diverse set of molecular targets.^[@bibr1-1535759719891983]^ In these 2 papers, the authors investigated the antiepileptogenic effects of targeting a different type of protein, the amino acid transporter, system xc- (Sxc).

System xc is a heterodimeric complex composed of xCT and 4F2 chains. It is located on the plasma membrane of astrocytes and, possibly, on other glial cells and neurons. System xc imports cystine and exports the excitatory neurotransmitter, glutamate, and thus differs from excitatory amino acid transporters (EAATs) that import glutamate in conjunction with sodium. The export of glutamate into the interstitium likely activates a variety of neuronal ionotropic and metabotropic glutamate receptors and Sxc-mediated glutamate export has been directly shown to activate extrasynaptic N-methyl-D-aspartate receptors.^[@bibr2-1535759719891983]^ In addition to its role in excitatory neurotransmission, the importation of cystine, a precursor of the antioxidant, glutathione, suggests that Sxc may be involved in regulating responses to oxidative stress. However, xCT deletion mice (xCT^--/--^) that do not have another superimposed neurological condition do not have increased expression of oxidative stress proteins, reduced hippocampal glutathione concentrations, or histological evidence of neuronal death.^[@bibr3-1535759719891983]^ Nevertheless, because altered Sxc-mediated cystine may affect oxidative stress differently in the presence of an additional neurological condition, Sxc function is being actively studied in the context of several neurological and psychiatric disorders including epilepsy.^[@bibr4-1535759719891983]^ The link between Sxc and epilepsy was strengthened by the findings of increased xCT protein expression in surgically resected hippocampi of patients with mesial temporal lobe epilepsy^[@bibr5-1535759719891983]^ and increased chemoconvulsant seizure thresholds in xCT^--/--^ mice.^[@bibr3-1535759719891983]^

While a previous study examined the effect of xCT deletion on seizure thresholds with acute chemoconvulsant administration,^[@bibr3-1535759719891983]^ the current 2 articles tested the effects of xCT deletion on epileptogenesis. The xCT deletion mouse used by Leclercq and colleagues (xCT^--/--^) was a targeted disruption of xCT exon 1,^[@bibr6-1535759719891983]^ while Sears et al studied xCT deletion in the subtle gray mouse (xCT^sut/sut^, Jackson 001310) which harbors a large spontaneous deletion in the xCT gene (Slc7a11^sut^) extending from intron 11 through exon 12. Importantly, these 2 papers evaluated the effect of xCT deletion in 3 separate models of epileptogenesis ([Table 1](#table1-1535759719891983){ref-type="table"}). In one model, self-sustained status epilepticus (SSSE), the proepileptogenic insult was prolonged convulsive status epilepticus (SE), a severe brain insult, but one known to produce epilepsy in human patients. The other 2 models used kindling paradigms in which repetitive administration of low-intensity electrical stimuli or low-dose chemoconvulsants initially produced small seizures but ultimately produced large ones. Leclercq et al used a 6 Hz corneal stimulation kindling paradigm in which low-intensity, brief, twice-daily, electrical stimulations of the cornea first elicit focal seizures but eventually produce focal to bilateral tonic-clonic seizures (FBTCS). Shears and colleagues used a chemical kindling protocol in which low doses of the γ-aminobutyric acid type A antagonist, pentylenetetrazol, first produce mild generalized seizures (myoclonic- and absence-like seizures) but, after repeated administration, reliably evoke generalized tonic-clonic seizures (GTCS). In addition to testing the effects of xCT deletion, Leclercq et al also determined the effects of another epileptogenic model, pilocarpine-evoked SE on biochemical activation of a putative Sxc signaling pathway in wild-type NMRI (Naval Medical Research Institute) mice as well as the effects of acute pharmacological Sxc inhibition on acute seizures evoked after post-SE epileptogenesis.
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  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                            SSSE                                                                     Corneal Kindle                                                                         PTZ Kindle                                                         Pilo SE
  ----------------------------------------- ------------------------------------------------------------------------ -------------------------------------------------------------------------------------- ------------------------------------------------------------------ ------------------------------------------------
  Mice                                      Wt vs xCT^---/---^C57BL/6J                                               Wt vs xCT^---/---^C57BL/6J                                                             Wt vs xCT^sut/sut^ C3H/HeSnJ                                       Wt NMRI

  Protocol                                  90 minutes amygdala electrical stim → 150 minutes SE → DZP termination   Twice-daily 3 seconds corneal stim until consistent FBTCS                              PTZ i.p. until GTCS on 3 consecutive days or day 21                Pilo i.p. → DZP termination at 3 hours

  xCT del effects on pre-epileptogenic sz   No effect on AD, induction and SSSE sz score                             No effect on % FBTCS or \# stimulations to full kindling/small reduction of sz score   Increased GTCS on day 1/ no effect on GTCS latency final 3 days    Not applicable

  Postepileptogenesis sz assessment         EEG monitoring/daily spontaneous seizure count                           Acute corneal stim/avg sz score and % FBTCS                                            Acute PTZ administration 10 days after last PTZ/% mice with GTCS   Acute corneal stim/sz \> 7 seconds

  Effect on post-SE/kindle sz?              xCT del reduced spontaneous sz                                           xCT del small reduced (small) sz score & % FBTCS\                                      xCT del reduced % kindled mice but not permanency                  SAS i.p. reduced acute sz only in kindled mice

  Histology                                 xCT del reduced post-SE activated microglia and astrocytes               ND                                                                                     No effect of xCT del on neuron number or mossy fiber sprouting     ND

  xCT expression                            No effect                                                                No effect                                                                              No effect                                                          Increased xCT protein 28 days.
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: avg, average; DZP, diazepam; EEG, electroencephalogram; FBTCS, focal to bilateral tonic--clonic seizure; GTCS, generalized tonic-clonic seizures; i.p., intraperitoneal; ND, not done; NMRI, Naval Medical Research Institute; Pilo, pilocarpine; PTZ, pentylenetetrazol; SAS, sulfasalazine; SE, status epilepticus; SSSE, self-sustained status epilepticus; stim, stimulation; sz, seizure.

It is possible that a genetic modification such as xCT deletion could reduce acute seizures associated with SE or kindling and thus appear to reduce epileptogenesis simply by blunting the initial proepileptogenic brain insult and not by modifying postinsult plasticity of the seizure network. As a clinical analogy, promptly terminating SE will reduce the probability that a patient will develop epilepsy, but acute SE treatments (eg, benzodiazepines) are not considered antiepileptogenic therapies. Because xCT^--/--^ mice had increased seizure thresholds in response to acute chemoconvulsant administration^[@bibr3-1535759719891983]^ it was important for both groups to assess the effects of xCT deletion on seizures before or during the epileptogenesis period ([Table 1](#table1-1535759719891983){ref-type="table"}). In the SSSE model, xCT deletion did not affect afterdischarge threshold or seizure score during SE induction or during the SSSE. For the corneal kindling model, there was no effect of xCT deletion on the percentage of mice experiencing a FBTCS or the number of stimulations required to reach a fully kindled state; however, xCT^--/--^ mice did have reduced mean initial seizure scores. In the PTZ kindling model, a greater percentage of xCT^--/--^ mice exhibited a GTCS on the first day of PTZ administration, a result opposite to what would be expected if xCT deletion was simply acting by reducing acute seizures. In addition, there were no differences in PTZ-evoked GTCS latency between wild-type and xCT^--/--^ mice.

In all 3 models, xCT deletion reduced seizures/seizure severity after the epileptogenic period ([Table 1](#table1-1535759719891983){ref-type="table"}). After SSEE, xCT^--/--^ mice had a significantly longer latency before the onset of the first spontaneous seizure as well as fewer spontaneous seizures. In the corneal kindling model, xCT^--/--^ mice had significantly fewer FBTCS as well as a lower mean seizure score; however, the magnitudes of both these effects were rather modest. In the PTZ kindling paradigm, a significantly smaller percentage (50%) of xCT^sut/sut^ mice were kindled relative to wild-type mice (81.5%). There was no difference in the permanency of the kindled state.

In addition to evaluating the effects of xCT deletion on epileptogenesis, Leclercq et al determined the effects of systemic administration of sulfasalazine (SAS), a Sxc inhibitor, on acute seizures after pilocarpine kindling. Sulfasalazine administered for 3 days before the corneal stimulation challenge reduced seizures by greater than 50%. Interestingly, there was no effect of SAS on corneal-evoked seizures in mice that did not undergo pilocarpine SE, a result suggesting that Sxc was involved in modulating the seizure circuit resulting from epileptogenesis but not the native seizure circuit.

The effects of xCT deletion on postinjury histology were determined in the SSSE and PTZ kindling models ([Table 1](#table1-1535759719891983){ref-type="table"}). After SSSE, hippocampi from wild-type mice, but not xCT^--/--^ mice exhibited significantly increased staining for both ionized calcium binding adaptor molecule-1 protein and glial fibrillary acidic protein, markers of microglia and astrocytic activation, respectively. After PTZ-kindling, neither wild-type nor xCT^sut/sut^ mice demonstrated hippocampal neuron loss or mossy fiber sprouting.

Resected hippocampi from human mesial temporal lobe epilepsy patients expressed increased xCT protein relative to autopsy controls.^[@bibr5-1535759719891983]^ However, in wild-type mice, PTZ kindling did not increase xCT mRNA and neither SSSE nor corneal kindling increased xCT mRNA or protein expression ([Table 1](#table1-1535759719891983){ref-type="table"}). In contrast, pilocarpine SE caused a significant increase in hippocampal xCT protein expression 28 days after SE and a time-dependent, albeit nonstatistically significant increase in xCT mRNA expression. This elevated postpilocarpine SE xCT expression was accompanied by increases in phospho-Akt, phosphorylated GSK-3β, phosphorylated eIF2α, and ATF4, components of the PI3K growth factor signaling pathway which may play a role in xCT expression.

These 2 studies are important because they provide preliminary evidence that Sxc may be a novel target for antiepileptogenic therapy. While EAATs are also being investigated for antiepileptogenic therapy,^[@bibr7-1535759719891983]^ Sxc may be better adapted for drug targeting. Unlike Sxc which exports glutamate, EAATs import it and thus their activity must be enhanced in order to reduce extracellular glutamate concentration, a pharmacologically more difficult problem than inhibition. In addition, because investigators are testing the effects of Sxc inhibition in several neurological and psychiatric disorders,^[@bibr4-1535759719891983]^ it is more likely that Sxc antagonists will be clinically available in contrast to niche compounds that are only useful for preventing epileptogenesis.

It is also significant that these investigators found xCT deletion significantly reduced seizures in three very different models of epileptogenesis including SE and focal and generalized kindling. The use of multiple models provides confidence that the effect would be observed in a variety of proepileptogenic insults and thus ultimately applicable to a greater spectrum of patients.

Finally, given the possible role of Sxc in oxidative stress responses, it was notable that the investigators found that xCT deletion reduced markers of activated microglia and astrocytes in the SSEE model and did not cause neuron loss or mossy fiber sprouting in the PTZ kindling model. This finding provides reassurance that Sxc inhibition would not likely worsen neurological injury.

While these studies provide solid preliminary evidence of antiepileptogenic effects, more study is required. Are the observed effects truly antiepileptogenic? Clearly, unconditional genetic deletion models cannot fulfill the requirements of an antiepileptogenic therapy; namely, one that is administered at the time of neurological insult and eventually withdrawn. In contrast to the acute chemoconvulsant models studied previously,^[@bibr3-1535759719891983]^ the authors did find that xCT deletion did not alter the initial seizures prior to the epileptogenesis period, evidence that xCT loss did not act by merely ameliorating the initial neurological insult. However, it is possible that unconditional xCT deletion may alter neural plasticity mechanisms prior to the insult and that these preexisting changes may be needed prior to the proepileptogenic insult. Similarly, it is possible that xCT deletion is providing an anti-seizure effect after the epileptogenic period and, if it were possible to restore xCT expression, seizures would worsen. Future experiments using an inducible genetic knockdown strategy^[@bibr8-1535759719891983]^ employing specific Scx inhibitors are needed to answer these questions.

In conclusion, these 2 studies are notable for identifying Sxc as new potential target for antiepileptogenic therapy. Future studies that elucidate the time course and mechanisms of action will reveal if this potentially "exciting" development translates to useful pharmacological intervention.
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